Global Cancer Monoclonal Antibodies Market
A monoclonal antibody drug in cancer. Cancer monoclonal antibodies may be used in combination with other cancer treatments. The destruction of cancer cells by another immune system process , Due to its specificity, monoclonal antibodies have at least adverse effects than other cancer treating drugs.
The market growth of cancer monoclonal antibodies is driven by increased prevalence of cancer worldwide. According to WHO, cancer is one of the leading causes of deaths worldwide. In 2012, there were around 14 mn new cases of cancer, 8.2 mn people died because of cancer and new cancer cases are projected to rise 70% in coming decades. In addition, monoclonal antibodies are proved to be less harmful than conventional non-targeted therapies. Increasing investment in the development of monoclonal antibodies, technological advancements. However, the high cost of development, stringent regulatory guidelines, long period of clinical trials, are some of the factors hindering growth of cancer monoclonal antibodies market. Monoclonal antibodies are very specific in nature and have limited targets.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-cancer-monoclonal-antibodies-market/#ulp-4H8Z4LpNMLEuOnnx
Cancer monoclonal antibodies market has been segmented based on application, type and conjugation, and distribution channel
Base on application, cancer monoclonal antibodies is segmented into
- Breast cancer
- Blood Cancer
- Liver Cancer
- Brain cancer
- Colorectal Cancer
- Others
Based on type of antibody, cancer monoclonal antibodies is segmented into
- Murine Antibodies
- Humanized Antibodies
- Chimeric Antibodies
Based on conjugation, cancer monoclonal antibodies is segmented into
- Immunocytokines
- immunoliposomes
- radioimmunotherapy
- Antibody Directed Enzyme Prodrug Therapy (ADEPT)
Based on distribution channel, cancer monoclonal antibodies market segmented into
- Hospital Pharmacies
- Retail Pharmacies
- Clinics
To view TOC of this report is available upon request @
Currently cancer monoclonal antibodies is a significant growth. The targeted and combination therapy drugs are leading in the market. Several market players collaborating to develop various types of cancers. In January 2017, AbCellera Biologics, Inc. collaborated with Pfizer Inc. for new therapeutic antibody discovery. AbCellera intends to use its monoclonal antibody (mAb) screening techniques in the discovery of function modulating antibodies against undisclosed membrane protein targets. National Institutes of Health (USA), National Cancer Institute (USA) and many others are collaborating and participating in cancer research and awareness activities.
Need more information about this report @
Geographically cancer monoclonal antibodies has been segmented into following regions. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Monoclonal antibodies among healthcare professionals in the region. According to the National Cancer Institute (NIH), an estimated 1,685,210 people are diagnosed in the United States and 595,690 people want the disease in 2016. Asia-Pacific region is expected to exhibit rapid growth due to rise in government spending on healthcare infrastructure, increasing R & D spending by healthcare and professional healthcare in the therapeutic use of monoclonal antibodies in the treatment of cancer. For instance, Government-led fund providers, as well as National Natural Science Foundation and National Basic Research Program of China, offer financial support to enterprises and universities to conduct monoclonal antibody research and development. The cancer monoclonal antibodies market in Latin-America. offer financial support to enterprises and universities to conduct monoclonal antibody research and development. The cancer monoclonal antibodies market in Latin-America. offer financial support to enterprises and universities to conduct monoclonal antibody research and development. The cancer monoclonal antibodies market in Latin-America.
Some of the players in cancer monoclonal antibodies are Merck & Co. Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Spectrum Pharmaceuticals (US), Eli Lilly and Company (US), Amgen Inc. (US ), Bristol-Meyer Squibb (US), Sanofi (France) and AstraZeneca (UK) to name a few.
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-cancer-monoclonal-antibodies-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firms, which follows a holistic approach to solve the needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and making better decisions. We provide consulting, syndicated and customized market research services based on our client needs.
Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI’s approachable strategies are to help you make keys to business growth. Precision Business Insights is the most valuable partner in the world
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): 1-866-598-1553